Literature DB >> 30201330

Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis.

Ivo P van de Peppel1, Frank A J A Bodewes2, Henkjan J Verkade3, Johan W Jonker4.   

Abstract

With the improved treatment of the pulmonary complications of cystic fibrosis (CF), gastrointestinal problems have become more important in the morbidity in CF. A hallmark of the gastrointestinal phenotype of CF, apart from pancreatic insufficiency, is a disruption of bile acid homeostasis. Bile acid homeostasis is important for many gastrointestinal processes including fat absorption, inflammation, microbial composition, as well as regulation of whole body energy metabolism. This review describes the impairment of bile acid homeostasis in CF, its possible consequences for gastrointestinal and metabolic complications and its potential as a target for therapy.
Copyright © 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bile acids; Cystic fibrosis; Intestine; Liver; Metabolism

Year:  2018        PMID: 30201330     DOI: 10.1016/j.jcf.2018.08.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  5 in total

1.  Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study.

Authors:  Felice Amato; Alice Castaldo; Giuseppe Castaldo; Gustavo Cernera; Gaetano Corso; Eleonora Ferrari; Monica Gelzo; Romina Monzani; Valeria Rachela Villella; Valeria Raia
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

2.  Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever.

Authors:  H R Wardill; C E M de Mooij; A R da Silva Ferreira; I P van de Peppel; R Havinga; H J M Harmsen; W J E Tissing; N M A Blijlevens
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-20       Impact factor: 3.333

3.  Mechanisms for Bile Acids CDCA- and DCA-Stimulated Hepatic Spexin Expression.

Authors:  Qi Lai; Yanhua Ma; Jin Bai; Min Zhuang; Shaofei Pei; Ni He; Junlin Yin; Baomin Fan; Zhaoxiang Bian; Guangzhi Zeng; Chengyuan Lin
Journal:  Cells       Date:  2022-07-10       Impact factor: 7.666

4.  CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis.

Authors:  Olaf Sommerburg; Susanne Hämmerling; S Philipp Schneider; Jürgen Okun; Claus-Dieter Langhans; Patricia Leutz-Schmidt; Mark O Wielpütz; Werner Siems; Simon Y Gräber; Marcus A Mall; Mirjam Stahl
Journal:  Antioxidants (Basel)       Date:  2021-03-19

5.  Infants with cystic fibrosis have altered fecal functional capacities with potential clinical and metabolic consequences.

Authors:  Alexander Eng; Hillary S Hayden; Christopher E Pope; Mitchell J Brittnacher; Anh T Vo; Eli J Weiss; Kyle R Hager; Daniel H Leung; Sonya L Heltshe; Daniel Raftery; Samuel I Miller; Lucas R Hoffman; Elhanan Borenstein
Journal:  BMC Microbiol       Date:  2021-09-15       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.